Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Candel Therapeutics (CADL) Receivables - Net (2020 - 2021)

Candel Therapeutics' Receivables - Net history spans 2 years, with the latest figure at $1.1 million for Q4 2021.

  • On a quarterly basis, Receivables - Net rose 72.44% to $1.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.1 million, a 72.44% increase, with the full-year FY2021 number at $1.1 million, up 72.44% from a year prior.
  • Receivables - Net hit $1.1 million in Q4 2021 for Candel Therapeutics, up from $191000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for CADL hit a ceiling of $1.1 million in Q4 2021 and a floor of $191000.0 in Q1 2021.